Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Paediatric Neuroblastoma
4.2.2 Rise in Awareness of Available Treatment Types
4.3 Market Restraints
4.3.1 High Research and Development Cost
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Chemotherpay
5.1.2 Surgery
5.1.3 Retinoid therapy
5.1.4 Others
5.2 By Risk Group
5.2.1 Low Risk
5.2.2 Intermediate Risk
5.2.3 High Risk
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 United Therapeutics Corporation
6.1.2 APEIRON Biologics AG
6.1.3 Baxter
6.1.4 APAC Biotech
6.1.5 Sun Pharmaceutical Industries, Inc.
6.1.6 Pfizer, Inc.
6.1.7 Bayer AG
6.1.8 MacroGenics, Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS